Danaher Corp
Close on Nov 2, 2026Market cap $160.26BP/E 40.5Yield –
Danaher Consolidated Adjusted EBITDA by Quarter
Consolidated Adjusted EBITDA (Non-GAAP Supplemental Data) ($M)
Danaher Consolidated Adjusted EBITDA: $2,108M in Q3 2026, up 12.3% from a year earlier.
Where the Q3 2026 figure comes from
Source: Danaher IR — nongaap_2026Q3 ↗
Disclosed in the Segment Overview table of Non-GAAP Reconciliations & Supplemental Data (fills gap where EBITDA ended in FY2023 and had no quarterly figures).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Consolidated Adjusted EBITDA (Non-GAAP Supplemental Data) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 2,108 | +12.3% | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2026 | Jun 30, 2026 | 1,894 | +5.0% | Danaher IR — nongaap_2026Q2 ↗ |
| Q1 2026 | Mar 31, 2026 | 1,988 | +5.7% | Danaher IR — nongaap_2026Q1 ↗ |
| Q4 2025 | Dec 31, 2025 | 2,129 | +0.5% | Danaher IR — nongaap_2025Q4 ↗ |
| Q3 2025 | Sep 30, 2025 | 1,877 | +6.0% | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2025 | Jun 30, 2025 | 1,803 | +3.1% | Danaher IR — nongaap_2026Q2 ↗ |
| Q1 2025 | Mar 31, 2025 | 1,880 | -2.2% | Danaher IR — nongaap_2026Q1 ↗ |
| Q4 2024 | Dec 31, 2024 | 2,119 | +5.2% | Danaher IR — nongaap_2025Q4 ↗ |
| Q3 2024 | Sep 30, 2024 | 1,771 | +3.1% | Danaher IR — nongaap_2025Q3 ↗ |
| Q2 2024 | Jun 30, 2024 | 1,748 | +0.2% | Danaher IR — nongaap_2025Q2 ↗ |
| Q1 2024 | Mar 31, 2024 | 1,923 | -6.3% | Danaher IR — nongaap_2025Q1 ↗ |
| Q4 2023 | Dec 31, 2023 | 2,015 | -20.7% | Danaher IR — nongaap_2024Q4 ↗ |
| Q3 2023 | Sep 30, 2023 | 1,718 | -23.2% | Danaher IR — nongaap_2024Q3 ↗ |
| Q2 2023 | Jun 30, 2023 | 1,745 | -27.9% | Danaher IR — nongaap_2024Q2 ↗ |
| Q1 2023 | Mar 31, 2023 | 2,052 | -18.3% | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2022 | Dec 31, 2022 | 2,541 | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q3 2022 | Sep 30, 2022 | 2,236 | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2022 | Jun 30, 2022 | 2,420 | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2022 | Mar 31, 2022 | 2,513 | – | Danaher IR — nongaap_ex_veralto ↗ |
Breakdown
What makes up consolidated Adjusted EBITDA
- Biotechnology — Adjusted EBITDA800 · Q3 2026
- Life Sciences — Adjusted EBITDA452 · Q3 2026
- Diagnostics — Adjusted EBITDA944 · Q3 2026
- Other / Corporate — Adjusted EBITDA-88 · Q3 2026
- Biên Adjusted EBITDA toàn công ty (Adjusted EBITDA Margin)32.2% · Q3 2026
- Biotechnology — Biên Adjusted EBITDA44.3% · Q3 2026
- Life Sciences — Biên Adjusted EBITDA24.2% · Q3 2026
- Diagnostics — Biên Adjusted EBITDA32.8% · Q3 2026
Cite this data
StockData. (2026). Danaher Consolidated Adjusted EBITDA ($M), quarterly Q1 2022–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/adj-ebitda-total
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.